These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 5485292)

  • 1. N-(t-aminoalkynyl)-substituted pyrrolidones as oxotremorine antagonists.
    Lindgren S; Lindquist A; Lindeke B; Svensson U; Karlén B; Dahlbem R; Blair MR
    Experientia; 1970 Nov; 26(11):1232-3. PubMed ID: 5485292
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonism of centrally mediated oxotremorine effects by a peripherally acting drug.
    Leszkovszky GP; Tardos L
    Eur J Pharmacol; 1971; 15(3):310-7. PubMed ID: 5159882
    [No Abstract]   [Full Text] [Related]  

  • 3. Acetylene compounds of potential pharmacological value. XXI. Further studies on the effect of branching the intermediate chain of N-(t-aminoalkynyl)-substituted succinimides and 2-pyrrolidones.
    Ringdahl B; Svensson U; Dahlbom R
    Acta Pharm Suec; 1975; 12(4):297-304. PubMed ID: 1199731
    [No Abstract]   [Full Text] [Related]  

  • 4. Acetylene compounds of potential pharmacological value. 18. N-(t-aminoalkynyl)-substituted 2-pyrrolidones, a new series of potent oxotremorine antagonists.
    Lindgren S; Lindquist A; Lindeke B; Svensson U; Karlén B; Dahlbom R
    Acta Pharm Suec; 1973 Dec; 10(6):435-40. PubMed ID: 4773112
    [No Abstract]   [Full Text] [Related]  

  • 5. Acetylene compounds of potential pharmacological value. XIX. N-(dialkylaminoalkynyl)-substituted succinimides and 2-pyrrolidones as partial cholinergic agonists.
    Svensson U; Dahlbom R
    Acta Pharm Suec; 1975; 12(3):209-14. PubMed ID: 1163240
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of distribution as a determinant of central anticholinergic specificity in a series of oxotremorine analogs.
    Karlén B; Jenden DJ
    Res Commun Chem Pathol Pharmacol; 1970 Jul; 1(4):471-8. PubMed ID: 5524258
    [No Abstract]   [Full Text] [Related]  

  • 7. 1-hydroxy-3-amino-pyrrolidone-2 (HA-966). II. Extrapyramidal aspects.
    Bonta IL; De Vos CJ; Grijsen H
    Arch Int Pharmacodyn Ther; 1969 Dec; 182(2):394-5. PubMed ID: 4984371
    [No Abstract]   [Full Text] [Related]  

  • 8. Acetylene compounds of potential pharmacological value. 8. N-(4-dialkylamino-2-butynyl)-substituted cyclic imides.
    Dahlbom R; Karlén B; George R; Jenden DJ
    J Med Chem; 1966 Nov; 9(6):843-6. PubMed ID: 5972043
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the pharmacological properties of deptropine, its methobromide--BS 7020a--and the 10,11-dehydro analogues.
    Timmerman H; Lavy UI; Mulder D
    Arch Int Pharmacodyn Ther; 1970 Oct; 187(2):291-300. PubMed ID: 4394744
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of atropine and dyflos on tremor and increase in whole brain acetylcholine produced by injection of oxotremorine in the rat.
    Cox B; Potkonjak D
    Br J Pharmacol; 1969 Mar; 35(3):521-9. PubMed ID: 5809741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylene compounds of potential pharmacological value. XII. Central and peripheral anticholinergic activity of t-aminoalkynyl esters of some carboxylic acids.
    Dahlbom R; Erbing B; Olsson K; George R; Jenden DJ
    Acta Pharm Suec; 1969 Jun; 6(3):349-58. PubMed ID: 5824849
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of desmethylimipramine and other "anti-tremorine" drugs on the metabolism of tremorine and oxotremorine in rats and mice.
    Sjöqvist F; Hammer W; Schumacher H; Gillette J
    Biochem Pharmacol; 1968 Jun; 17(6):915-34. PubMed ID: 5661354
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis and pharmacology of N-(4-diethylamino-2-butynyl)-succinimide (DKJ 21), a new central anticholinergic agent.
    Dahlbom R; Karlen B; George R; Jenden DJ
    Life Sci; 1966 Sep; 5(17):1625-31. PubMed ID: 5970685
    [No Abstract]   [Full Text] [Related]  

  • 14. [Age dependent differences in the action and metabolization of tremorine and oxotremorine in chicks].
    Zimmermann B; Klinger J; Oelssner W; Fischer HD; Westermann K; Meyer FP
    Acta Biol Med Ger; 1970; 25(1):161-7. PubMed ID: 5489671
    [No Abstract]   [Full Text] [Related]  

  • 15. N-(perhydroazepinoalkynyl)- and N-(perhydroazocinoalkynyl) succinimides as oxotremorine antagonists.
    Lindqvist A; Lindgren S; Lindeke B; Karlén B; Dahlbom R; Blair MR
    J Pharm Pharmacol; 1970 Sep; 22(9):707-8. PubMed ID: 4395168
    [No Abstract]   [Full Text] [Related]  

  • 16. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
    Eicholzer A; Ogren SO
    J Pharm Pharmacol; 1977 Oct; 29(10):609-11. PubMed ID: 21240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of some beta adrenergic blocking agents on the central and peripheral actions of tremorine and oxotremorine.
    Leslie GB; Hayman DG; Ireson JD; Smith S
    Arch Int Pharmacodyn Ther; 1972 May; 197(1):108-11. PubMed ID: 4402325
    [No Abstract]   [Full Text] [Related]  

  • 18. Motor disturbance induced by tremorine and oxotremorine.
    Jurna I; Nell T; Schreyer I
    Naunyn Schmiedebergs Arch Pharmakol; 1970; 267(1):80-98. PubMed ID: 4393397
    [No Abstract]   [Full Text] [Related]  

  • 19. [On the antagonistic effect of pyrone compounds of the kava rhizome (Piper methysticum Forst) against 1,4-dipyrrolidino-2-butyne].
    Meyer HJ; Dierstein M
    Arzneimittelforschung; 1965 Nov; 15(11):1344-7. PubMed ID: 5899870
    [No Abstract]   [Full Text] [Related]  

  • 20. Acetylene compounds of potential pharmacological value. XVI. N-(perhydroazepinoalkynyl)- and N-(perhydroazocinoalkynyl)succinimides.
    Lindquist A; Lindgren S; Lindeke B; Karlén B; Dahlbom R; Blair MR
    Acta Pharm Suec; 1972 Apr; 9(2):93-8. PubMed ID: 5030544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.